Health Care · Biological Products, (No Diagnostic Substances)

SRRK Scholar Rock Holding Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1727196108 filings
Russell 2000

SRRK at a glance

Scholar Rock Holding Corp (SRRK, SEC CIK 1727196) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 27, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Scholar Rock Holding Corp (SRRK) reported revenue of $0 and a net loss of $377.9 million. Diluted EPS was -$3.29.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Scholar Rock Holding Corp (SRRK) shares worth $1.8 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by AKKARAJU SRINIVAS on October 26, 2026 of 48,988 shares at $41.59 per share.
  • In the last 90 days, SRRK insiders reported 6 open-market purchases ($12.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $12.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
6 buys · 0 sells
Net +$12.0M
13F holders
31 funds
$1.8B · −2 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 1.01 · Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Biopharmaceutical company developing selective monoclonal antibodies targeting latent growth factors for rare neuromuscular diseases
  • New products emphasized: Apitegromab subcutaneous formulation and SRK-439 anti-latent myostatin antibody, both in clinical development in 2026
  • Strategic shift: Transitioning to global commercial-stage biotech; appointed new CEO and expanded U.S./European commercial teams (~50 employees)
  • Notable metric: Submitted BLA for apitegromab in SMA in Jan 2025; received FDA Priority Review and EMA MAA acceptance in March 2025
  • Unique fact: Apitegromab is first myostatin inhibitor with positive Phase 3 SAPPHIRE study outcome and plans to target additional indications including infants under 2 years and FSHD

Risk Factors

  • FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization
  • Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site
  • Supply chain risk: reliance on limited third-party manufacturers for materials, with potential interruptions or quality issues impacting clinical/commercial supplies
  • Competitive risk: dependence on continued availability of approved SMN-targeted treatments (e.g., nusinersen, risdiplam) for apitegromab trials; limited access could halt trials
  • Financial risk: ongoing net losses and urgent need for additional capital to fund development and commercialization of apitegromab, SRK-181, SRK-439

Management Discussion & Analysis

  • Net loss $377.9M in 2025 vs $246.3M in 2024, operating expenses up 52.6% to $384.6M from $252.1M
  • R&D expense $208.4M (+12.9%), G&A expense $176.2M (+161.0%), driven by commercial launch prep for apitegromab
  • Apitegromab R&D costs rose 14.7% to $89.8M; SRK-181 decreased 75.8%, SRK-439 decreased 22.9%
  • Cash, cash equivalents, and securities $367.6M at 2025 YE, down $69.7M YoY; net cash used in operations $300.0M
  • Raised $91.7M from ATM stock sales, $50M from debt facility, $63.8M from warrant exercises in 2025
  • FDA CRL for apitegromab due to third-party fill-finish issues; resubmission pending resolution, Phase 2 trial in FSHD planned mid-2026
  • Management expects ongoing substantial expenses for R&D, commercialization, and infrastructure build ahead of potential apitegromab launch

AI summary of the SRRK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added commercialization risk: FDA approved ISEMBYLD on September 11, 2026, making U.S. launch execution critical to revenue and profitability
  • Most material regulatory update: third-party fill-finish facility received OAI classifications in 2025 and 2026, delaying EU approval and forcing MAA resubmission
  • Regulatory pricing risk: CMS finalized GLOBE on October 2, 2026, requiring incremental Medicare Part B rebates beginning January 1, 2027
  • Near-term operational risk: single-source apitegromab drug substance and fill-finish suppliers expose commercial supply to disruptions and batch failures
  • Financial risk: ongoing net losses and additional capital requirements remain necessary to fund ISEMBYLD commercialization and pipeline development

Management Discussion & Analysis

  • Q3 revenue $0.6M from ISEMBYLD, versus $0 in Q3 2025
  • Gross margin approximately 98.7%, based on $0.6M revenue and $8,000 cost of revenue
  • Best-performing program SRK-439 R&D costs $2.9M, up 77.4% YoY; apitegromab costs $20.0M, down 6.5%
  • Cash, equivalents and marketable securities $413.6M, up $46.0M from December 31, 2025
  • Operating cash use $234.2M; financing provided $280.0M, including $160.8M ATM proceeds and $197.7M debt proceeds

AI summary of the SRRK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $205 million cash proceeds from sale of Rare Pediatric Disease Priority Review Voucher to BioNTech
  • Voucher awarded after FDA approval of ISEMBYLD on September 11, 2026

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Scholar Rock’s financial and operating results for the quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1, the company’s earnings release

Item 7.01: Regulation FD Disclosure

  • Conference call scheduled for November 10, 2026 at 8:00 a.m. ET
  • Slides cover financial and operating results for quarter ended September 30, 2026

Item EX-99.1: Item EX-99.1

  • ISEMBYLD U.S. launch underway, generating $0.6 million Q3 revenue after September 11 FDA approval
  • Early demand broad across physicians and patients, but sustained treatment, reimbursement and market adoption remain key execution risks

Item EX-99.2: Item EX-99.2

  • Q3 2026 earnings update: ISEMBYLD U.S. launch underway, with initial inventory shipments generating $0.6 million
  • Early commercial reach: over one-third of Top 140 SMA centers prescribing, with demand across children and adults
Filed Sep 15, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • FDA approved ISEMBYLD for spinal muscular atrophy patients aged 2 and older receiving SMN2-targeted treatment
  • Management corrected prior statement: FDA requires a pregnancy safety study covering complications and birth outcomes
Filed Sep 14, 2026Full analysis →

Item 8.01: Other Events

  • FDA approval of ISEMBYLD™ (apitegromab-mstn) for spinal muscular atrophy
  • Label covers adults and children aged 2 years and older receiving survival SMN2-targeted treatment

Item EX-99.1: Item EX-99.1

  • FDA approval transforms Scholar Rock into a commercial-stage company with ISEMBYLD for SMA patients ≥2 years receiving SMN2-targeted therapy
  • Phase 3 SAPPHIRE showed 2.2-point HFMSE improvement versus placebo at 10 mg/kg, with nominal p=0.0121

Item 7.01: Regulation FD Disclosure

  • FDA approval of ISEMBYLD for SMA patients ages 2 and older receiving SMN2-targeted treatment
  • Commercial launch opportunity in SMA, expanding Scholar Rock’s potential revenue base

Item EX-99.2: Item EX-99.2

  • FDA-approved ISEMBYLD launch underway for SMA patients aged 2 and older receiving SMN2-targeted treatment
  • Phase 3 showed 2.2-point HFMSE improvement versus placebo, supporting differentiated motor-function benefit

AI summaries of SRRK 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SRRK

Don't miss the next SRRK filing

  • Alerts as it files. A push when SRRK files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SRRK, by share count.
  • Ask anything. An AI agent that reads every SRRK filing and answers with sources.

SRRK alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
AKKARAJU SRINIVASBuyOct 26, 2026$41.59
AKKARAJU SRINIVASBuyOct 26, 2026$41.59
AKKARAJU SRINIVASBuyOct 23, 2026$41.31
AKKARAJU SRINIVASBuyOct 23, 2026$41.82
AKKARAJU SRINIVASBuyOct 23, 2026$41.82
AKKARAJU SRINIVASBuyOct 23, 2026$41.31
Woods KeithGSep 24, 2026-
Hallal DavidGSep 21, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue--$0
Operating Income-$171.3M-$252.1M-$384.6M
Net Income-$165.8M-$246.3M-$377.9M
Balance Sheet
Total Assets-$474.9M$404.3M
Equity$225.2M$368.6M$245.5M
ROE-73.6%-66.8%-154.0%
Per Share
EPS$-1.99$-2.47$-3.29
Cash Flow
Operating CF--$200.9M-$300.0M
CapEx$71K$98K$602K

Source: XBRL data in Scholar Rock Holding Corp (SRRK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SRRK share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SRRK shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$1.83B
Q2 202633$2.91B
Q1 202629$2.24B
Q4 202526$1.93B
Q3 202527$1.59B
Q2 202529$1.54B
Q1 202526$899.5M
Q4 202423$1.11B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SRRK filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
4Oct 27, 2026--
4Sep 25, 2026--
4Sep 23, 2026--
8-KSep 15, 2026Analysis-
8-KSep 14, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KAug 6, 2026Analysis-
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 5, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis

Related Health Care companies

All Health Care →

SRRK SEC filings: frequently asked questions

Are SRRK insiders buying or selling?

In the last 90 days, Scholar Rock Holding Corp (SRRK) officers, directors and 10% owners reported 6 open-market purchases worth $12.0 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SRRK stock?

As of September 30, 2026, the largest Scholar Rock Holding Corp (SRRK) holders among the 13F filers tracked by SignalX were BlackRock ($461.9 million), T. Rowe Price Group ($283.4 million), Vanguard Capital Management LLC ($232.2 million), State Street Corp ($211.4 million), Vanguard Portfolio Management LLC ($144.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SRRK's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Scholar Rock Holding Corp (SRRK) reported revenue of $0 and a net loss of $377.9 million. Diluted EPS was -$3.29. The figures come from the XBRL data in the 10-K.

What are the main risks in SRRK's latest 10-K?

In the 10-K filed March 3, 2026, Scholar Rock Holding Corp (SRRK) flagged: FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization. Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site. (AI summary of the Risk Factors section.)

What did SRRK report in its latest 8-K?

Scholar Rock Holding Corp (SRRK) filed an 8-K on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). $205 million cash proceeds from sale of Rare Pediatric Disease Priority Review Voucher to BioNTech.

What are the latest SRRK SEC filings?

Scholar Rock Holding Corp (SRRK) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 27, 2026.

What is SRRK's SEC CIK number?

Scholar Rock Holding Corp (SRRK)'s SEC Central Index Key (CIK) is 1727196. EDGAR lists every SRRK filing under that number.

Ask anything about SRRK

The research agent reads SRRK's filings, financials, insider trades and 13F holders, then answers with sources.